Overview

506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory cutaneous T-cell lymphoma
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)